Unravelling Intestinal Fibrosis in Ulcerative Colitis

ConditionsUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Fibroblast Activation Protein Inhibitor

Trial statusRecruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging

Eligibility criteria

Qualifiers

Adults with confirmed diagnosis of UC - Group 1 criterion: ≥18 years of age regardless of gender

Group 2 criterion: ≥30 years of age for males and ≥40 years of age for females

Active disease confirmed by endoscopy (endoscopic Mayo score ≥ 2)

Indication to start treatment with filgotinib

Disqualifiers

Pregnancy

Unable to provide informed consent

Colorectal carcinoma or high-grade dysplasia

Trial design

Treatments tested in this trial

Fibroblast Activation Protein Inhibitor

Treatment groups

10 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Lead sponsor

Source ClinicalTrials.gov